Concerns that U.S. technology stocks are in a bubble crept higher in Deutsche Bank’s quarterly survey of institutional investors. On a scale from 1 to 10, from “no bubble” to “extreme bubble”, ...
Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback